The major aims were to determine the clinical safety of ARGX-111 in patients bearing tumors overexpressing the MET protein and/or harboring MET amplification, pharmacokinetics, pharmacodynamics and preliminary evidence of anti-tumor activity. This evidence concerns the gene MET and neoplasm.